FBIO Fortress Biotech, Inc.

3.95
+0.11  (3%)
Previous Close 3.84
Open 3.82
Price To book 4.05
Market Cap 198.81M
Shares 50,332,000
Volume 76,864
Short Ratio 20.01
Av. Daily Volume 190,762

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 preliminary data due mid-2017 with full data due by the end of the year.
CAEL‐101
AL amyloidosis
Phase 2 data in adults due 1H 2019.
CEVA101
Severe Traumatic Brain Injury
Phase 2 data in children due 1H 2018.
CEVA101
Severe Traumatic Brain Injury
Phase 2 data due 1H 2018.
Pepvax vaccine
Cytomegalovirus (CMV)
Phase 1/2 initiated October 2016.
CK‐101
Solid tumors - cancer
Phase 2 trial ongoing with Phase 3 to be initiated in 2017.
N-acetyl-D-mannosamine (ManNAc)
GNE Myopathy
Phase 3 to be initiated in 2017 with data due in 2018.
IV Tramadol
Post-operative Pain
Phase 2 data due 2H 2017.
Triplex vaccine
Cytomegalovirus (CMV)

Latest News

  1. Fortress Biotech (FBIO) Looks Good: Stock Adds 5% in Session
  2. Avenue Therapeutics Receives Notice of Allowance for a New Patent Application Covering Methods of Administration for Intravenous Tramadol
  3. Mustang Bio Reports First Quarter 2017 Financial Results and Recent Corporate Highlights
  4. ETFs with exposure to Fortress Biotech, Inc. : May 15, 2017
  5. Fortress Biotech, Inc. :FBIO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
  6. Fortress Biotech reports 1Q loss
  7. Fortress Biotech Reports First Quarter 2017 Financial Results and Recent Corporate Highlights
  8. BioXcel Therapeutics, Inc. (BTI) Is Launched with Phase 2-ready Programs Addressing Unmet Needs in Immuno-oncology and Neuroscience
  9. Fortress Biotech Announces Final Patient Dosed in Phase 1B Trial of CAEL-101 for the Treatment of AL Amyloidosis
  10. Checkpoint Therapeutics to Present at PIONEERS 2017 Presented by Joseph Gunnar & Co.
  11. Fortress Biotech to Present at PIONEERS 2017 Presented by Joseph Gunnar & Co.
  12. Mustang Bio Announces Appointment of Manuel Litchman, M.D., as President and Chief Executive Officer
  13. Fortress Biotech Announces Orphan Drug Designations for CAEL-101 in Amyloidosis
  14. Checkpoint Therapeutics Reports Preclinical Data for Two Oncology Programs
  15. Fortress Biotech to Present at BioCentury’s 24th Annual Future Leaders in the Biotech Industry Conference
  16. ETFs with exposure to Fortress Biotech, Inc. : March 30, 2017
  17. Fortress Biotech, Inc. :FBIO-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
  18. Fortress Biotech (FBIO) Catches Eye: Stock Moves Up 8.3%
  19. Checkpoint Therapeutics to Present Preclinical Data at the American Association for Cancer Research Annual Meeting 2017
  20. Fortress Biotech Reports Financial Results for the Fourth Quarter and Full Year Ended December 31, 2016